4.7 Article

Prognostic Significance of Nestin Expression in Resected Non-small Cell Lung Cancer

Journal

CHEST
Volume 139, Issue 4, Pages 862-869

Publisher

AMER COLL CHEST PHYSICIANS
DOI: 10.1378/chest.10-1121

Keywords

-

Funding

  1. Japan Society for the Promotion of Science [C19590365]
  2. Grants-in-Aid for Scientific Research [23590414] Funding Source: KAKEN

Ask authors/readers for more resources

Background: Nestin is a class 6 intermediate filament protein expressed in stem/progenitor cells during CNS development. Nestin expression has been detected in many kinds of tumors and was reported in a recent small-scale study in non-small cell lung cancer (NSCLC). We investigated the relationships between nestin expression and clinicopathologic parameters and determined its prognostic significance concerning survival in patients with resected NSCLC. Methods: Nestin expression in tumor cells was studied immunohistochemically in 171 consecutive patients with NSCLC, and associations with clinicopathologic parameters were evaluated. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect of nestin expression on survival. Results: Nestin expression was observed in tumor cell samples in 27 of the 171 patients with NSCLC (15.8%). Nestin had only cytoplasmic expression. Clinicopathologically, nestin expression was significantly associated with squamous cell carcinoma (P=.001), poorer differentiation (P=.007), lymph node metastasis (P=.008), intratumoral vascular invasion (P=.003), intratumoral lymphatic invasion (P=.008), pleural invasion (P=.039), and poorer prognosis (P<.001). Multivariable analysis confirmed that nestin expression increased the hazard of death after adjusting for other clinicopathologic factors (hazard ratio, 2.75; 95% CI, 1.39-5.46). Conclusions: The present study suggests that nestin expression is a prognostic indicator of poorer survival probability for patients with resected NSCLC and may be used as a potential marker for select patients who should receive adjuvant chemotherapy. CHEST 2011; 139(4):862-869

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available